The Human Papilloma Virus (HPV) is a recognized carcinogenic factor. Previous studies have shown a possible association between HPV and bladder cancer, however HPV serology has not been reported. In this study, we assessed the correlation between bladder cancer and HPV positive serology.
INTRODUCTION AND OBJECTIVES:
The Human Papilloma Virus (HPV) is a recognized carcinogenic factor. Previous studies have shown a possible association between HPV and bladder cancer, however HPV serology has not been reported. In this study, we assessed the correlation between bladder cancer and HPV positive serology.
METHODS: Using NHANES, a large nationally-representative population-based survey, we gathered clinical and demographic data on all patients with a diagnosis of bladder cancer over from [2007] [2008] [2009] [2010] and analyzed their HPV serology status. We assessed the effects of positive serologic results for HPV18, HPV16, HPV11, and HPV6 on the rates of bladder cancer diagnosis.
RESULTS: Over the four-year period there was a weighted population of 155,650,000 Americans. The prevalence of HPV positive serology was as follows: HPV18 -5.5%, HPV16 -13.2%, HPV11 -6.4%, HPV6 -17.4%. There were 443,948 bladder cancer cases. Among cases there was a higher prevalence of male gender (80% vs 53%, p [ 0.0056), Caucasian race (93% vs 66%, p [ 0.001), and HPV6 positive serology (18.1% vs 17.6%, p [ 0.0005). There was no difference among the other three HPV types. On logistic regression controlling for race, gender, and smoking status, increasing body weight (OR 1.01, p <0.0001) and HPV6 positivity (OR 1.9, p<0.0001) were associated with increased odds of bladder cancer diagnosis while HPV11 positivity (OR 0.23, p<0.0001) was associated with a decreased odds of bladder cancer diagnosis.
CONCLUSIONS: Prior research has shown that there is a relationship between HPV and bladder cancer, but this relationship has previously been incompletely defined. In this large, nationally representative database, we describe a significant association of HPV6 positive serology with a diagnosis of bladder cancer. This finding is striking and might affect future investigation into the pathophysiologic basis of this relationship.
Source of Funding: None

MP05-13 HEPATITIS B SEROLOGY IS A NOVEL RISK FACTOR FOR BLADDER CANCER
Kevin Shee*, Lael Reinstatler, Lebanon, NH; Kristian Stensland, Burlington, MA; John D. Seigne, Einar F. Sverrisson, Lebanon, NH INTRODUCTION AND OBJECTIVES: Chronic Hepatitis B (HepB) or Hepatitis C (HepC) infection has been well-established as an important risk factor for the development of hepatocellular carcinoma (HCC). Because HepB/C infection has been directly linked to oncogenesis, in part due to the regulation of p53 activity, it was hypothesized that there may be an association between HepB/C infection and the development of other cancer types, specifically bladder cancer.
METHODS: A nationally representative cross-sectional analysis was performed using demographic and clinical data from the National Health and Nutrition Examination Survey (NHANES) database. Data from patients with any bladder cancer diagnosis over a four-year period were obtained, and positivity for Hepatitis B Surface Antibody (HBAbS), Hepatitis B Core Antibody (HBAbC), and Hepatitis C Antibody (HCAb) were analyzed as risk factors using logistic regression analyses controlling for age, smoking status, race, and BMI.
RESULTS: From the NHANES database, 447,694 bladder cancer cases and 287,300,485 controls were included in the study. Cases tended to be significantly older than controls (71.8 vs 48.0 years old, p<0.0001), and were more likely to be Caucasian (94.7% vs 63.3%, p<0.0001). HBAbS, HBAbC, and HCAb were not significantly different between the two groups. On logistic regression, HBAbs was found to be significantly enriched in bladder cancer cases vs controls (OR[10.4, p<0.0001 CONCLUSIONS: In this study using a large, nationally representative database, HBAbs, which is a marker of HepB serology, was found to be significantly associated with a diagnosis of bladder cancer. To our knowledge, this is the first study to report a significant relationship between HepB and bladder cancer. These findings warrant validation in additional cohorts and investigation into the specific pathophysiologic mechanisms of increased bladder cancer risk.
Source of Funding: none
MP05-14 NATIONWIDE MORTALITY TRENDS IN BLADDER VS LUNG CANCER: DATA FROM THE CAUSES OF UROLOGIC DEATH IN AMERICA (CUDA) STUDY
Jyoti Chouhan*, Ethan Matz, Marc Colaco, Amy Pearlman, Winston-Salem, NC; James Lovato, WInston-Salem, NC; Ryan Terlecki, Winston-Salem, NC INTRODUCTION AND OBJECTIVES: The Centers for Disease Control (CDC) lists urothelial cancer as a tobacco-related malignancy (TRM). The National Health Interview Survey found declining rates of tobacco use among United States (U.S.) adults. Data from outside the U.S. suggests that, while risk of lung cancer mortality (LCM) may decrease after tobacco cessation, risk of bladder cancer mortality (BCM) appears stable. Also, racial disparities have been noted for incidence and mortality in TRM. We sought to determine the trend in BCM relative to LCM for whites, blacks and Hispanics over the past decade.
METHODS: The CUDA study is a comprehensive review of allcause mortality data from death records warehoused by the CDC from 2005-2016, and to our knowledge, the first to do so relative to urologic disease. The total number of deaths per year for this database ranged from 2.31-2.63 million. Subset analysis was performed using ICD-10 codes C67 (bladder cancer) and C33-34 (trachea/bronchus/lung cancer) and stratified by race and ethnicity. Time series regression analysis was performed for the entire interval.
RESULTS: Over the study interval, BCM accounted for 0.61-0.69%, 0.36-0.43% and 0.38-0.43% of total mortality for whites, blacks, and Hispanics, respectively. A significant increase was seen in all groups; (p<0.01, R2[0.87, F(1, 11)[64.47, [white], P<0.01, R2[0.62, F(1, 11)[16.35 [Black], p[0.019, R2[0.44, F(1, 11)[7.75 [Hispanic] . See Graphs 1a-c.
LCM accounted for 5.9-7.1%, 5.3-6.4%, and 3.3-4.0% of total mortality for whites, blacks and Hispanics, respectively. A significant decrease was seen in all groups; (p<0.01, R2[0.89, F(1, 11)[82.46, p<0.01 [white], p<0.01, R2[0.63, F(1, 11)[17.65 [Black], p<0.01, R2[0.82, F(1, 11)[44.47, [Hispanic] . See Graphs 2a-c.
CONCLUSIONS: Over time, BCM and LCM show inverse trends. This may suggest differences in organ response to tobacco exposure, recovery following cessation, natural history over time, or attribution bias. This data is highly relevant for patient counseling. Future studies are needed, and mortality data will need to be viewed alongside incidence.
